Matthew Pletcher, PhD

Title: Division Head of Gene Therapy Research & Technical Operations

Organization: Astellas Gene Therapies

Bio: Mathew Pletcher, Ph.D. is Division Head of Gene Therapy Research & Technical Operations for Astellas Gene Therapies. He is responsible for advancing the company’s pipeline from discovery through to IND-enabling preclinical development and for all Manufacturing, Supply Chain, Facilities & Engineering, and Process & Analytical Development functions. Prior to joining Astellas Gene Therapies (formerly Audentes Therapeutics) in July 2020, Mr. Pletcher worked at Roche Pharma where he was Head of Rare Diseases Research and Early Development, and prior to that, Head of Discovery. Previously, he served as Acting Chief Scientific Officer at Autism Speaks and earlier as Vice President, Head of Genomic Sciences. He also spent eight years working in Pfizer’s Rare Diseases Research Unit in various scientific roles of increasing responsibility including Director, Rare Diseases Research Unit. Dr. Pletcher also founded and leads a non-profit foundation, Fund for Sight, supporting research and resources for families and children impacted by the genetic disease his daughter inherited called Leber Congenital Amaurosis. He holds a Bachelor of Science in Biology from Duquesne University and a Ph.D. in Human Genetics form Johns Hopkins School of Medicine.

2021 FUTURES: Gene Therapy & Gene Editing Symposium

Information and updates on the gene therapy and gene editing landscape from experts in the field.

**We experienced a technical issue during this session. Please reach out with questions to Futures@CureDuchenne.org if needed.

Beth Belluscio, MD, PhD

Global Clinical Lead, Rare Neurological Disorders

Pfizer

See more from same speaker

Olivier Danos, PhD

Chief Scientific Officer

REGENXBIO

See more from same speaker

Emil Kakkis, PhD

CEO & President

Ultragenyx Pharmaceutical

See more from same speaker

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

See more from same speaker

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

See more from same speaker

Carl Morris, PhD

Chief Scientific Officer

Solid Biosciences

See more from same speaker

Eric Olson, PhD

Chief Scientific Advisor

Vertex Pharmaceuticals

See more from same speaker

Matthew Pletcher, PhD

Division Head of Gene Therapy Research & Technical Operations

Astellas Gene Therapies

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker

Genine Winslow, MSc

CEO & President

Chameleon Biosciences

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years